Iskalni niz:
išči po
išči po
išči po
išči po
Vrsta gradiva:
Jezik:
Št. zadetkov: 3
Pregledni znanstveni članek
Oznake:
Background In the recent years, the number of patients treated with anticoagulant therapy is increasing. Among them, there is also an increased number of patients with renal insufficiency. Due to changes in coagulation andfibrinolityc system activity these patients are at increased risk of bleeding ...
Leto: 2008 Vir: dLib.si Digitalna knjižnica Slovenije
Izvirni znanstveni članek
Oznake: zaviralci PCSK9;monoklonska protitelesa;siRNA;študije iz resničnega sveta;zdravilo inclisiran;zdravilo evolokumab;zdravilo alirokumab;LDL-C;intoleranca na statine;kardiovaskularni učinki;PCSK9 inhibitors;monoclonal antibodies;real-world study;inclisiran;evolocumab;alirocumab;statin intolerance;cardiovascular outcomes;
Background and Aims: Randomized trials showed efficacious lipid-lowering with PCSK9 inhibitors (PCSK9i), but real-world treatment is often limited by statin-associated side effects (SASE). We quantified the effectiveness, safety and cardiovascular outcomes of alirocumab, evolocumab and inclisiran in ...
Leto: 2026 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Izvirni znanstveni članek
Oznake: hypercholesterolemia;universal screening;preschoolers;total cholesterol;genetic testing;
Familial hypercholesterolemia (FH) is the most common metabolic disease, with prevalence estimated between 1:250 and 1:300. The affected individuals have a significantly higher risk for developing atherosclerosis and cardiovascular disease (CVD) compared to non-affected individuals. Early CVD can be ...
Leto: 2025 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Št. zadetkov: 3
Ključne besede:
Leto izdaje:
Avtorji:
Repozitorij:
Tipologija:
Jezik: